Baxter(US:BAX) Financial Modeling Prep·2025-10-31 00:13Core Insights - Baxter International Inc. is a global healthcare company providing essential medical products, including devices, pharmaceuticals, and biotechnology, with a focus on Medical Products and Therapies [1] - The company faces competition from major players like Johnson & Johnson and Medtronic [1] Financial Performance - Baxter reported a third-quarter adjusted EPS of 69 cents, exceeding management's guidance of 58-62 cents and Wall Street's estimate of 60 cents [3] - The company's sales for the third quarter were $2.84 billion, reflecting a 5% year-over-year increase on a reported basis and a 2% increase on an operational basis, closely aligning with the consensus of $2.88 billion [4] - Despite the positive EPS results, Baxter lowered its 2025 guidance, which negatively impacted investor sentiment [3][6] Segment Performance - The Medical Products and Therapies segment reported sales of approximately $1.33 billion, showing a 1% decline on both a reported and operational basis, primarily due to reduced sales in the Infusion Therapies and Technologies division [5][6] - Strong global demand for other products partially offset the decline in the Medical Products and Therapies segment [5] Market Outlook - Stifel Nicolaus set a price target of $22 for Baxter, indicating a potential upside of approximately 14.73% from the current stock price of $19.18 [2] - Despite the optimistic price target, Baxter's stock has experienced a significant drop, reaching a 52-week low [2][6]